What does the evidence say about Hmb Muscle Retention Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Hmb Muscle Retention Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - The pathogenesis of malnutrition is complex and multifactorial, involving reduced nutrient intake, altered metabolism, and malabsorption []. [Trigui Amal (2026); evidence level 2] - Malnutrition is a major risk factor for sarcopenia [], which is defined by the European Working Group on Sarcopenia in Older People (EWGSOP) as low muscle strength combined with low muscle mass or quality []. [Trigui Amal (2026); evidence level 2] - Malnutrition and sarcopenia in cirrhosis are associated with greater risk of decompensation, higher infection rates, prolonged hospitalization, and reduced quality of life []. [Trigui Amal (2026); evidence level 2] - 1 2 3 4 5 6 7 Malnutrition affects over 80% of patients with chronic liver disease awaiting liver transplantation (LT) []. [Trigui Amal (2026); evidence level 2] - As life expectancy increases, age-associated declines in muscle strength, metabolic flexibility, immune responsiveness, and cognitive resilience have become major contributors to morbidity and diminished quality of life. [Chen Zhigang (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.